WRN Inhibitor Q15: Structural Models for Microsatellite Instability-High Cancer Treatment

Q15, a novel Werner Syndrome RecQ helicase inhibitor, demonstrated complete tumor regression at 40 mg/kg in preclinical models. This dataset, published by Qibang Sui in June 2026, contains structural models in PDB format, likely detailing the interaction between the inhibitor and its target. The 763.6 KB resource supports research into synthetic lethal therapies for microsatellite instability-high tumors.

Use Cases

• Analyzing protein-ligand binding interactions based on the described WRN-HRO761 complex structure.
• Comparing the structural features of spirocyclic compounds and benzo-fused heterocyclic analogs mentioned in the description.
• Supporting rational drug design for WRN helicase inhibitors based on the solvent-exposed region target.
• Evaluating in silico pharmacokinetic properties of candidate molecules like Q15 and HRO761.

Strengths

• Includes structural data for a promising drug candidate (Q15) with reported complete tumor regression at 40 mg/kg.
• Data is associated with a specific, peer-reviewed scientific discovery published on figshare in 2026.

Limitations

• The dataset is very small at 763.6 KB, indicating limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Likely generated from X-ray crystallography or molecular modeling as part of a structure-guided drug discovery project.

Freshness

Last updated 2026-06-03 18:37:26; freshness should be verified.